A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors.

被引：0
|
作者：
Schmid, P
Kiewe, P
Kuehnhardt, D
Korfel, A
Lindemann, S
Giurescu, M
Reif, S
Thiel, E
Possinger, K
机构：
[1] Humboldt Univ, Berlin, Germany
[2] Schering AG, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：147S / 147S
页数：1
相关论文
共 50 条
  • [41] A phase I study of PT-112 in advanced solid tumors.
    Karp, Daniel D.
    Camidge, D. Ross
    Bryce, Alan Haruo
    Jimeno, Jose
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC)
    Morrow, P. H.
    Divers, S. G.
    Provencher, L.
    Luoh, S.
    Petrella, T. M.
    Giurescu, M.
    Fielding, L.
    Wang, Y.
    Hortobagyi, G. N.
    Vahdat, L. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Phase I study using continuous intravenous (Cl) KOS-862 (Epothilone D) in patients with solid tumors.
    Holen, KD
    Syed, S
    Hannah, AL
    Binger, K
    Wood, L
    Zhou, Y
    Cropp, GF
    Johnson, RG
    Rowinsky, E
    Wilding, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 133S - 133S
  • [44] Phase I and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors.
    Marshall, JL
    Ramalingam, S
    Hwang, JJ
    Ramanathan, R
    Malik, S
    Egorin, M
    Hannah, A
    Cropp, GF
    Johnson, RG
    Belani, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 145S - 145S
  • [45] Phase I study of pazopanib and ixabepilone in patients with solid tumors.
    Ganesan, Chitra
    Obulareddy, J.
    Bliss, Robin L.
    Dudek, Arkadiusz Z.
    CANCER RESEARCH, 2013, 73 (08)
  • [46] A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors.
    Townsley, C. A.
    Siu, L. L.
    Pedro-Salcedo, M. San
    Liu, L.
    Wakelee, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] A phase I study with CRx-026, a novel dual action agent, in patients (pts) with advanced solid tumors.
    von Hoff, DD
    Gordon, M
    Turner, J
    White, E
    Nichols, MJ
    Elliott, PJ
    Mendelson, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 210S - 210S
  • [48] A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
    Rasco, Drew W.
    Lakhani, Nehal J.
    Li, Yufeng
    Men, Lichuang
    Wang, Hengbang
    Ji, Jiao
    Tang, Yuefen
    Liang, Zhiyan
    Amaya, Alex
    Estkowski, Kathy
    Sun, Joan
    Huang, Yingjie
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Phase I clinical and pharmacokinetic study of irofulven in combination with oxaliplatin in patients with advanced solid tumors.
    Alexandre, J
    Tchen, N
    Berthault-Cvitkovic, F
    Misset, JL
    Benettaib, B
    Kahatt, C
    Raymond, E
    Weems, G
    MacDonald, JR
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9057S - 9057S
  • [50] Final results of the phase I study of the novel epothilone BMS-247550 administered weekly in patients (pts) with advanced solid tumors
    Awada, A
    Jones, S
    Piccart, M
    Calvert, S
    Crabeels, D
    McCabe, S
    Holtkamp, C
    Lebwohl, D
    Voi, M
    Burris, H
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S41 - S41
12345